• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
  • Guest Content
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
No Result
View All Result
Home News

Breakthrough coronavirus drug could prevent 80% of cases from worsening

Trials of a new, inhaled coronavirus treatment found that hospital patients taking the drug had a dramlower risk of needing intensive care

Henry Goodwin by Henry Goodwin
2020-07-20 11:09
in News
Credit;PA

Credit;PA

FacebookTwitterLinkedinEmailWhatsapp

Trials of a new, inhaled coronavirus treatment found that hospital patients taking the drug had an almost 80 per cent lower risk of needing intensive care.

The treatment – developed by Synairgen, a Southampton-based biotech company – uses a protein called interferon beta which the body produces when it gets a viral infection.

Early results of the study found that patients who received the drug, known as SNG001, were more than twice as likely to recover from Covid-19 as those who received a placebo.

The drug is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, and aims to stimulate an immune response.

It is hoped that a direct dose of the protein into the lungs will trigger a strong antiviral response, even in patients with already-weakened immune systems.

‘Very promising’

The initial findings are very promising, suggesting that the drug could cut the odds of a Covid-19 patient developing severe symptoms – like requiring a ventilator – by 79 per cent.

Patients were also two to three more likely to recover to the point where their everyday activities were unencumbered by their illness, Synairgen claims, with breathlessness markedly reduced.

The average time patients spent in hospital is said to have been reduced by a third for those receiving the new drug – down from an average of nine days to six days.

The double-blind trial involved 101 volunteers who had been admitted for treatment for Covid-19 infections at nine UK hospitals. Half were given the drugs, while the other half received a placebo.

RelatedPosts

UK inflation shoots up unexpectedly driven by 18.3% hike in food prices

Gary Lineker posts thinly veiled tweet ahead of Johnson’s Partygate probe

Johnson’s partygate defence ‘complete and utter nonsense’, say Covid bereaved

The key people Boris Johnson mentions in his evidence

Stock market rules force Synairgen to report the preliminary results of the trial. The findings have not been published in a peer-reviewed journal, and the full data from the trial is yet to be made available.

‘Game changer’

Nonetheless the scientist in charge of the trial – Professor Tom Wilkinson – described the results as a potential “game changer”.

Professor Wilkinson, professor of respiratory medicine at the University of Southampton and trial chief investigator, added: “The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lungs’ immune response, enhancing protection, accelerating recovery and countering the impact of Sars-CoV-2 virus.”

Synairgen will now present its findings to medical regulators around the world, to see what further information they require in order to approve the treatment.

That process usually takes months, but the government has said it will attempt to fast-track Andy promising coronavirus treatment.

Professor Stephen Holgate, co-founder of Synairgen, said the treatment “restores the lungs’ ability to neutralise the virus, or any mutation of the virus or co-infection with another respiratory virus such as influenza or RSV, as could be encountered in the winter if there is a resurgence of Covid-19.”

Related: Coronavirus outbreak confirmed at NHS Test and Trace centre

Content Protection by DMCA.com

Since you are here

Since you are here, we wanted to ask for your help.

Journalism in Britain is under threat. The government is becoming increasingly authoritarian and our media is run by a handful of billionaires, most of whom reside overseas and all of them have strong political allegiances and financial motivations.

Our mission is to hold the powerful to account. It is vital that free media is allowed to exist to expose hypocrisy, corruption, wrongdoing and abuse of power. But we can't do it without you.

If you can afford to contribute a small donation to the site it will help us to continue our work in the best interests of the public. We only ask you to donate what you can afford, with an option to cancel your subscription at any point.

To donate or subscribe to The London Economic, click here.

The TLE shop is also now open, with all profits going to supporting our work.

The shop can be found here.

You can also SUBSCRIBE TO OUR NEWSLETTER .

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending

Elevenses: Exposing the Tories’ Deepfake Illegal Immigration Bill

Elevenses: Rishi’s Finest Hour

Elevenses: Fear and Loathing in the New Conservatives

More from TLE

‘Dieselgate’ probably led to the deaths of 210 Brits

Restaurant Review: Orasay

Rejoin EU by-election candidate is former Tory who thinks Brexit is broken

UK joins US in withdrawing staff and families from Ukraine embassy

BlackRock Throgmorton Trust – Impressive run continues

Sacha Baron Cohen asks judge to dismiss Roy Moore lawsuit over ‘paedophile detector’ joke

Petition to rescind Tony Blair knighthood passes half a million signatures

‘As bad as the pandemic’: Martin Lewis sounds energy bills alarm

Ousted Labour MP received breast cancer diagnosis during election campaign

Weather forecast, alerts and UVB index for London, Saturday 3 April 2021

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

Contact

Editorial enquiries, please contact: [email protected]

Commercial enquiries, please contact: [email protected]

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.